Replies to post #368285 on Anavex Life Sciences Corp (AVXL)

[mrplmer]

Missling rolls the dice way too often. German ego.

[XenaLives]

You stated "I just think it became less likely with this poster."

Did you figure in the fact that evidence for current SOC=0 now that the plaque attackers have been outed?

Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years
MARCH 16, 2022 • INVESTOR RELATIONS
ADUHELM continued to reduce two key Alzheimer’s disease pathologies, amyloid beta plaques and p-tau181, in patients treated for up to two and a half years
Data from both Phase 3 studies also show that clinical decline was reduced in participants who had plasma p-tau181 reduction at 78 weeks
These data further inform the scientific evidence for amyloid as a surrogate biomarker and the importance of continuation of treatment

https://investors.biogen.com/news-releases/news-release-details/long-term-phase-3-data-show-aduhelmr-continues-reduce-underlying

[JWC3]

It’s good that you aren’t skeptical! But, what does bring sceptical actually mean? Spreads germs?

[hnbadger1]

Thanks for your “glass half empty “ thoughts on the poster.
Because as we know, the FDA has dozens of very promising AD candidates lined up. Especially all those Amyloid prospects.

[Steady_T]

I'm missing why you think the odds of an AA and P4 became lower.

We know that the FDA likes biochemical data. This seems to provide a lot of that. The activation of so many genes after dosing with 2-73 seems to provide MAJOR support for the MOA of 2-73. To me one of the weaknesses of the 2-73 story is what is the basis of the MOA. This data provides a solid basis for how 2-73 generates the results it seems to do.

I think the odds of an AA are not high in part because of the fiasco with Aduhelm. Even so I think the odds have improved rather than decreased.

I look forward to your thinking on this.

[crescentmotor]

Or flip it around and ask, why has Accelerated Approval for PDD not been discussed let alone granted?

Do we know if a DSMB was put in place for the Alzheimer's trial?